Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

MLA

Rossing, Peter, et al. Dapagliflozin and New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials. Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.core.ac.uk....9bcba60a3ab0e42f4a7930b596803c84&authtype=sso&custid=ns315887.

APA

Rossing, P., Inzucchi, S. E., Vart, P., Jongs, N., Docherty, K. F., Jhund, P. S., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., DeMets, D. L., Bengtsson, O., Lindberg, M., Langkilde, A. M., Sjöstrand, M., Stefansson, B. V., Karlsson, C., … DAPA-CKD and DAPA-HF Trial Committees and Investigators. (2022). Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.

Chicago

Rossing, Peter, Silvio E Inzucchi, Priya Vart, Niels Jongs, Kieran F. Docherty, Pardeep S. Jhund, Lars Køber, et al. 2022. “Dapagliflozin and New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.core.ac.uk....9bcba60a3ab0e42f4a7930b596803c84&authtype=sso&custid=ns315887.